Suzhou Sunland Pharmaceutical Co., Ltd. has been long focusing on the research and development and industrialization of pharmaceutical-grade active substances and effective skin care raw materials, and is committed to providing safe, effective and proven solutions for clinical treatment and high-end skin care.The company's ActiBiso™ AA 70W ( azelaic acid 70%) is gradually establishing its important position in the management of skin problems such as acne, pigment abnormalities and rosacea due to its unique preparation process and extensive clinical application value.
Product introduction
ActiBiso™ AA 70W (azelaic acid 70%) is prepared by self-assembly and packaged azelaic acid and hydroxypropylcyclodextrin under alkaline conditions, which significantly improves the stability and skin permeability of azelaic acid. This raw material can be used in dermatological surface preparations, functional skin care products and related medical and health products, providing high-quality choices for the upstream and downstream of the industrial chain.
Mechanism and clinical value of multi-target action
Acne treatment
Selective bacteriostasis: Inhibit Propionibacterium acnes and Staphylococcus epidermidis, while maintaining the stability of normal skin flora.
Regulation and control of anti-inflammation: By reducing the levels of reactive oxygen species (ROS) and inflammatory factors, the swelling and pain can be alleviated.
Keratin renewal: Promote the exfoliation of old and waste keratin, smooth pores and normal keratinization recovery.
Clinical results: After 8 weeks of continuous use, inflammatory acne decreased by 78% and non-inflammatory acne decreased by 72%.
Pigmentation and chloasma
Selective blackout inhibition: only acts on abnormally active melanocytes to avoid the effects on normal skin tone.
Multipath inhibition: blocking tyrosinase activity and melanin transport, thus reducing pigment production.
Prevention of anti-melanism: anti-inflammatory mechanism reduces post-inflammatory pigmentation.
Rosace and skin barrier repair
Erythema improvement: Inhibit angiogenesis-related factors and improve facial erythema.
Enhancement of barrier: Promote ceramide synthesis and improve skin barrier function.
Symptom relief: Reduce TRPV1 receptor sensitivity and reduce burning and discomfort.
Applicable groups
ActiBiso™ AA 70W is suitable for the following clinical and functional skin care scenarios:
- Moderate to severe inflammatory acne
- Post-acne pigmentation (PIH) and post-inflammatory erythema (PIE)
- Rose acne management
- Chloasma and other pigment abnormalities
- Requirements for coarsepores and improvement of skin texture
Market application and prospect
Market scale: the global acne treatment market is expected to reach $8.5 billion by 2025; The annual growth rate of efficacy skin care products market in China is over 25%.
Consumer demand: The demand for products with quick response, safety, gentleness and clinical data support continues to grow.
Future development direction
Technology Trends:
- Complex formula that synergizes with ingredients such as nicotinamide, retinol, and citron acid
- Customize concentration and application scenarios based on skin type and problem customization
Market expansion:
- Acne Care for Men
- Post-medical repair (laser, microneedle, etc.)
- Acne prevention and treatment for teenagers
Conclusion
As an innovative raw material for the key research and development and promotion of Suzhou Sunland Pharmaceutical, ActiBiso™ AA 70W (azelaic acid 70%) provides reliable solutions for complex skin problems such as acne, pigmentation and rosacea with its scientific mechanism, clinical data and application value.
In the future, Sunland Pharmaceutical will continue to promote the in-depth application of high-concentration azelaic acid in the fields of dermatology and effective skin care, helping the industry achieve a dual balance between efficiency and safety.